Astellas Pharma Inc (ALPMY)
10.70
0.00 (0.00%)
USD |
OTCM |
Nov 15, 16:00
Astellas Pharma Enterprise Value: 23.34B for Nov. 14, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 14, 2024 | 23.34B |
| November 13, 2024 | 23.41B |
| November 12, 2024 | 23.74B |
| November 11, 2024 | 24.25B |
| November 08, 2024 | 24.18B |
| November 07, 2024 | 24.41B |
| November 06, 2024 | 24.18B |
| November 05, 2024 | 24.59B |
| November 04, 2024 | 25.15B |
| November 01, 2024 | 25.06B |
| October 31, 2024 | 25.09B |
| October 30, 2024 | 26.20B |
| October 29, 2024 | 25.02B |
| October 28, 2024 | 24.37B |
| October 25, 2024 | 24.49B |
| October 24, 2024 | 24.81B |
| October 23, 2024 | 24.66B |
| October 22, 2024 | 25.08B |
| October 21, 2024 | 25.25B |
| October 18, 2024 | 25.18B |
| October 17, 2024 | 24.83B |
| October 16, 2024 | 24.61B |
| October 15, 2024 | 24.72B |
| October 14, 2024 | 25.09B |
| October 11, 2024 | 25.15B |
| Date | Value |
|---|---|
| October 10, 2024 | 25.38B |
| October 09, 2024 | 25.04B |
| October 08, 2024 | 25.17B |
| October 07, 2024 | 25.15B |
| October 04, 2024 | 25.08B |
| October 03, 2024 | 24.95B |
| October 02, 2024 | 24.68B |
| October 01, 2024 | 24.56B |
| September 30, 2024 | 24.68B |
| September 27, 2024 | 24.92B |
| September 26, 2024 | 25.00B |
| September 25, 2024 | 25.06B |
| September 24, 2024 | 25.13B |
| September 23, 2024 | 25.45B |
| September 20, 2024 | 25.31B |
| September 19, 2024 | 25.42B |
| September 18, 2024 | 25.49B |
| September 17, 2024 | 24.97B |
| September 16, 2024 | 25.29B |
| September 13, 2024 | 25.17B |
| September 12, 2024 | 25.99B |
| September 11, 2024 | 26.17B |
| September 10, 2024 | 26.08B |
| September 09, 2024 | 26.29B |
| September 06, 2024 | 25.86B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
20.30B
Minimum
Apr 15 2024
31.58B
Maximum
Feb 11 2020
25.73B
Average
25.67B
Median
Jun 02 2022
Enterprise Value Benchmarks
| Pfizer Inc | 204.39B |
| Takeda Pharmaceutical Co Ltd | 72.05B |
| Nxera Pharma Co Ltd | 818.86M |
| PeptiDream Inc | 2.175B |
| Healios KK | 117.61M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 241.22M |
| Revenue (Quarterly) | 3.035B |
| Total Expenses (Quarterly) | 2.728B |
| EPS Diluted (Quarterly) | 0.1343 |
| Gross Profit Margin (Quarterly) | 80.74% |
| Profit Margin (Quarterly) | 7.95% |
| Earnings Yield | 0.54% |
| Operating Earnings Yield | 0.54% |
| Normalized Earnings Yield | 0.2548 |